Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 11, 2020 16:10 ET | Source: Beyond Air™

Beyond Air® Reports Financial Results for Second Quarter of Fiscal Year 2021 and Provides Business Update

Submitted a premarket approval (PMA) to the FDA for LungFit™ PH to treat persistent pulmonary hypertension of the newborn (PPHN) Expect patient enrollment to begin next week for the acute viral...
November 11, 2020 07:30 ET | Source: Beyond Air™

Beyond Air® Submits Premarket Approval Application to FDA for LungFit™ PH to Treat Persistent Pulmonary Hypertension of the Newborn

Potential to revolutionize nitric oxide therapy by eliminating need for cumbersome cylinders creating improved economics and safety in hospital setting Will be subject to a 180-day review period by...
October 23, 2020 08:00 ET | Source: Beyond Air™

Beyond Air® Schedules Second Fiscal Quarter 2021 Financial Results Conference Call and Webcast

GARDEN CITY, N.Y., Oct. 23, 2020 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO)...
October 21, 2020 07:00 ET | Source: Beyond Air™

Beyond Air® Approved to Initiate Clinical Study at 150 ppm Nitric Oxide with LungFit™ for the Treatment of Acute Viral Pneumonia Including COVID-19

Patients with pneumonia caused by any virus, including SARS-CoV-2, will be considered for enrollment Study scheduled to start in November 2020 GARDEN CITY, N.Y., Oct. 21, 2020 (GLOBE NEWSWIRE) --...
October 19, 2020 10:01 ET | Source: Beyond Air™

Beyond Air® Presents In Vivo Solid Tumor Data Confirming In Situ Cancer Vaccination with a Single Injection of Gaseous Nitric Oxide at the AACR Conference on Tumor Immunology and Immunotherapy

New in vivo data for colon cancer show anti-tumor immunity in 100% of mice In vivo breast cancer data show a significant delay in challenge tumor uptake GARDEN CITY, N.Y., Oct. 19, 2020 (GLOBE...
October 19, 2020 07:15 ET | Source: Beyond Air™

Beyond Air® Presents Data Showing Anti-Coronavirus Activity of Nitric Oxide at the CHEST Annual Meeting 2020

In vitro data support development of nitric oxide as a potential coronavirus therapy that acts within hours These data suggest that the LungFit™ system may be effective for both prevention and...
October 19, 2020 07:00 ET | Source: Beyond Air™

Beyond Air® Presents Pilot Bronchiolitis Data at the CHEST Annual Meeting 2020

150 ppm nitric oxide was statistically significant compared to both control and 85 ppm nitric oxide arms on the primary and key secondary endpoints All treatment groups had similar safety profiles...
October 16, 2020 08:00 ET | Source: Beyond Air™

Beyond Air® Presents Positive New Preclinical Data for the Use of a Single Injection of Gaseous Nitric Oxide as a Novel In situ Cancer Vaccination

GARDEN CITY, N.Y., Oct. 16, 2020 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO)...
September 30, 2020 08:00 ET | Source: Beyond Air™

Beyond Air® to Present Data on Nitric Oxide in the Treatment of Solid Tumors at the American Association for Cancer Research (AACR) Conference on Tumor Immunology and Immunotherapy

GARDEN CITY, N.Y., Sept. 30, 2020 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO)...
September 11, 2020 08:00 ET | Source: Beyond Air™

Beyond Air to Present at the Oppenheimer & Co. Fall Healthcare Life Sciences and MedTech Summit

GARDEN CITY, N.Y., Sept. 11, 2020 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO)...